Target type: molecularfunction
Catalysis of the reaction: S-nitrosoglutathione + NADH + H+ = S-(hydroxysulfenamide)glutathione + NAD+. [PMID:11260719, PMID:27094420, PMID:30795534]
S-nitrosoglutathione reductase (NADH) activity catalyzes the reduction of S-nitrosoglutathione (GSNO) to glutathione (GSH) and nitric oxide (NO). This reaction is important for maintaining cellular redox homeostasis and regulating NO signaling. The enzyme utilizes NADH as a cofactor to transfer electrons to GSNO, resulting in the cleavage of the S-N bond and the release of NO. This activity plays a crucial role in various cellular processes, including: 1) detoxification of reactive nitrogen species, such as GSNO, which can cause oxidative stress and damage cellular components. 2) regulation of NO signaling pathways, as the enzyme can modulate NO levels in cells. 3) control of protein S-nitrosylation, a post-translational modification that regulates protein function. 4) modulation of cellular redox state, as the enzyme contributes to the balance between reduced and oxidized glutathione. 5) regulation of vasodilation and blood pressure, as NO is a potent vasodilator. S-nitrosoglutathione reductase (NADH) activity is a key enzyme in the cellular response to oxidative stress and NO signaling, and its dysregulation is implicated in various diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Aldo-keto reductase family 1 member A1 | An aldo-keto reductase family 1 member A1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P14550] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
zopolrestat | zopolrestat: structure given in first source | ||
valproic acid | valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem. Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. | branched-chain fatty acid; branched-chain saturated fatty acid | anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent |
fr 74366 | |||
tolrestat | tolrestat: RN & structure given in first source | naphthalenes | EC 1.1.1.21 (aldehyde reductase) inhibitor |
octyl gallate | gallate ester | food antioxidant; hypoglycemic agent; plant metabolite | |
lidorestat | lidorestat: might prove useful in treating chronic diabetic complications; structure in first source | ||
fidarestat | fidarestat: structure given in first source | ||
minalrestat | minalrestat: a vasoactive agent | isoquinolines | |
sorbinil | sorbinil : An azaspiro compound having a monofluoro-substituted chromane skeleton spiro-linked to an imidazolidinedione ring. sorbinil: aldose reductase inhibitor | azaspiro compound; chromanes; imidazolidinone; organofluorine compound; oxaspiro compound | antioxidant; EC 1.1.1.21 (aldehyde reductase) inhibitor |
epalrestat | epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy. | monocarboxylic acid; thiazolidines | EC 1.1.1.21 (aldehyde reductase) inhibitor |
idd 594 | Idd 594: structure in first source | ||
caffeic acid phenethyl ester | phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component. | alkyl caffeate ester | anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent |